TriAltus Bioscience (AL, USA) has announced the launch of a new affinity chromatography resin for the cl7/im7 protein purification system, with double the binding capacity of the original resin for the single-step protein purification system.
Browsing: Drug development
American biotechnology product development company, Thermo Fisher Scientific (MA, USA), has announced the official opening of a Customer Solution Center in Shanghai, China.
High-resolution mass spectrometry: an essential tool for DMPK studies of novel peptide-based modalities
In this editorial Simone Esposito (IRBM, Italy) explores how HRMS has become a well established alternative to multiple reaction monitoring for DMPK profiling and discusses the use of HRMS for DMPK studies of nove peptide-based modalities.
Brexit or no Brexit? The question that has been weighing on the UK for the past 3 years will soon have an answer (hopefully). Read this commentary from Zamas Lam (QPS; DE, USA) discussing how Brexit relates to the future of drug discovery, preclinical and clinical drug development.
Bioanalysis Zone is proud to announce the 2019 Bioanalysis Outstanding Contribution Award winner – find out who has won this year’s award here!
In this editorial Helen Shen (QPS; PA, USA) discusses the projected growth in the global small molecule discovery market and what impact this may have on the management of chronic diseases as well as what to look for when partnering with a CRO for small molecule studies.
Researchers have discovered unique populations of neurons in the spinal cords of patients who died of amyotrophic lateral sclerosis that could be utilized as potential drug targets.
In this interview, Hanna Ritzén (Mercodia; Uppsala, Sweden) provides an insight into her recent article on classification of commercial LBA kits for biomarkers, and why this area of bioanalysis is important.
Frontage Holdings Corporation announces successful initial public offering on the Hong Kong stock exchange
Frontage Holdings Corporation has recently announced that they have begun trading on the main board of the stock exchange of Hong Kong.
This commentary from Bioanalysis focuses on the status of drug detection with metal nanoparticles as ultrasmall labels in colorimetric-based methods.